Coppertone, Dr. Scholl’s On The Block As Bayer Narrows Consumer Health Focus
This article was originally published in The Rose Sheet
Executive Summary
Bayer will sell Coppertone sunscreen and Dr. Scholl’s foot care brands to focus on growing its core consumer health brands. Although the plan represents ‘failure” in turning around sales for both brands, it is a ‘sensible’ move, say analysts.
You may also be interested in...
Bayer Consumer Health Yet To Turn Corner Due To Supply, Innovation Detours
Company needs to get beyond a supply problem for products including iconic Bayer Aspirin brand and heat up Coppertone sun care and sunscreen product sales with line extensions to help drive the consumer health business to heights envisioned as part of an expansion a few years ago.
Perrigo's OTC Core Could Expand To Include National Brands
Submitting an OTC switch of Nasonex would be a first for Perrigo, as would marketing a national brand OTC if the switch is approved. In tandem with announcing divesture of Perrigo's Rx business, CEO Uwe Rohrhoff says marketing national brands in some OTC categories fits in the company's "value-creation road map."
Prestige's Monistat, Summer's Eve Brands Key Drivers In Consumer Health Focus
BC and Goody's OTC acetaminophen formulations perhaps are the firm's most known consumer health brands but they account for 12% of its revenues while its Monistat and Summer's Eve brands drove 27% of its sales in its latest quarter. The feminine hygiene brands' contribution, says a Jefferies analyst , will only grow with the firm selling its household care brands to focus entirely on the consumer health market.